Latest Circulating Tumor Cell Stories

Ikonisys, a provider of next-generation, cell-based diagnostic solutions, has reported positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research UK. The study validates the company's CellOptics platform and proprietary digital microscope, the Ikoniscope, as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC) in the blood. The...

Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, today announced positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research U.K. (CRUK), the country's leading cancer charity. The study validates the company's CellOptics(R) platform and proprietary digital microscope, the Ikoniscope(R), as a viable method for quickly and easily detecting...

The Advalytix product team of Olympus is initiating a collaborative study with The University of Texas M. D. Anderson Cancer Center to characterize circulating tumor cells in breast cancer patients. The study combines Advalytix's sensitive AmpliGrid molecular analysis platform, multiplex primer design, and integrated workflow to analyze expression of multiple target genes in single tumor cells. "Using AmpliGrid, we plan to genetically fingerprint subpopulations of tumor cells with a...

Immunicon Corporation (OTCBB:IMMC.OB) announced today that Immunicon Corporation and its wholly-owned subsidiaries completed their previously announced sale of substantially all of their assets to Veridex, LLC ("Veridex") in a sale conducted under the provisions of Section 363 of the U.S. Bankruptcy Code and approved by the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") on July 30, 2008. Veridex paid Immunicon $31,320,023 in cash, subject to certain...

RARITAN, N.J., Aug. 1 /PRNewswire/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation (BULLETIN BOARD: IMMC) and its wholly-owned subsidiaries. The assets acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells...

RARITAN, N.J., July 25 /PRNewswire/ -- An international, prospective clinical trial found the number of circulating tumor cells (CTCs) is a strong indicator of progression-free and overall survival among metastatic colorectal cancer patients, according to a report published in the July 1 issue of the Journal of Clinical Oncology. The study, conducted in the US, the Netherlands, and the United Kingdom, found that metastatic colorectal cancer patients with fewer than three circulating tumor...

U.S. medical scientists say they've found circulating tumor cells reveal genetic signatures of dangerous lung cancers, possibly leading to targeted therapy. Massachusetts General Hospital investigators say a microchip-based device they developed -- called the CTC chip -- can detect and analyze tumor cells in the bloodstream to determine the genetic signature of lung tumors. When the device is ready for larger clinical trials, it should give us new options for measuring treatment response,...

Researchers at Massachusetts General Hospital Cancer Center and Harvard Medical School reported Wednesday that an investigational procedure that extracts lung cancer cells from blood samples may also provide valuable feedback to doctors on the effectiveness of individualized treatments.The researchers obtained cancer cells from the blood samples of 27 study participants, each with non-small-cell lung cancer that had spread. They discovered a correlation in the number of circulating cancer...

OncoVista Innovative Therapies Inc. (OTC BB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, today announced that it has successfully completed the acquisition of additional shares of AdnaGen AG (Hanover, Germany), increasing its ownership from 85% to over 95% of the issued and outstanding shares of the company. OncoVista's Chief Executive Officer, Alexander L. Weis, Ph.D., commented, "The increase in our...

Immunicon Corporation (NASDAQ:IMMC) announced today that the FDA has cleared the CellSearch™ Circulating Tumor Cell (CTC) Kit as an aid in the monitoring of patients with metastatic prostate cancer. A sample of the patient's blood is processed with the CellSearch Kit using the CellTracks® System to capture and count CTCs. This clearance represents another expansion to claims for the kit, which is now cleared for three of the four most prevalent cancers. The CellSearch CTC kit...